A2RL
The Abu Dhabi Autonomous Racing League (A2RL), which made its impressive debut this April at the Yas Marina Circuit, has announced the next phase of its challenge with the Drone Champions League (DCL), the world's premier professional drone racing organization. Building on the success of its inaugural event, the A2RL Drone Race continues to advance the frontiers of autonomous technology, merging human skill with innovative advancements in autonomous flight.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240724188405/en/
The Abu Dhabi Autonomous Racing League (A2RL) x Drone Champions League (DCL) (Graphic: AETOSWire)
The Autonomous Drone Race will bring together teams from across the globe, welcoming established drone racing teams, research institutions and enthusiastic 'rookies.' All competitors will vie for a thrilling prize purse of US$1million, as they strive to achieve maximum agility and speed while successfully maneuvering through objects in the way. Registration is now open at a2rl.io, and interested teams are invited to apply for the competition. All entries will undergo a rigorous selection process to identify the successful competing teams. Those who pass the screening will be invited to participate in a series of tasks that will allow the judging panel to assess the teams' proficiency in using an open-source simulator to fly a drone autonomously. The grand finale will be held in April 2025, where the winner will be determined.
Organized by ASPIRE, A2RL integrates artificial intelligence (AI), autonomy and extreme sports to push the boundaries of future mobility and is spotlighted as the largest autonomous racing league in the world. The A2RL extreme autonomous drone race will see competing researchers program drones to navigate through a sequence of gates, avoiding obstacles, using onboard sensors and computational power. The main goal of the race is to set a benchmark for achieving maximum innovation in algorithms while using minimal sensor technology in complex environments.
As with all grand challenges, the A2RL Drone Challenge will also include a STEM focus and high-school students will be welcome to be a part of the competition.
Announcing the new competition, H.E. Faisal Al Bannai, Secretary General of ATRC, said: “It's only when you experiment in extreme conditions that you really discover new boundaries or breakthroughs in science. We’re inspiring global collaboration, driving technological progress, and creating a future where autonomous solutions transform industries and improve lives.”
Stephane Timpano, CEO at ASPIRE, said: “This is an exciting evolution of our A2RL extreme racing series. DCL is a like-minded partner with years of invaluable drone racing experience. Together, we are not only adding a new autonomous dimension to drone racing but are also demonstrating the limitless possibilities of unmanned aerial vehicles through this competition.”
Markus Stampfer, Executive Chair of Drone Champions AG, the organizer of the Drone Champions League (DCL), said: “At DCL, our mission has always been to push the boundaries of drone racing. Having successfully merged the worlds of virtual and physical drone racing, partnering with ASPIRE to advance autonomous drone flying is a natural next step for us. We are thrilled to bring our extensive experience and expertise to this pioneering competition, supporting ASPIRE with the knowledge we've gained from years of developing race drones and working with the world's best drone pilots.”
By advancing drone technology, this race aims to make drone usage accessible for all countries, ultimately reducing costs and driving innovation across industries such as health and logistics.
For media enquiries please contact: comms@a2rl.io or ATRC@edelman.com
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240724188405/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom